{
    "hands_on_practices": [
        {
            "introduction": "The ability of *Candida albicans* to switch between a unicellular yeast and a filamentous hyphal form is a hallmark of its pathogenesis. This morphological transition is not just a change in appearance; it fundamentally alters the cell's interaction with its environment. In this problem, you will use basic geometric principles to explore one of the most critical biophysical consequences of this switch: the change in the surface area-to-volume ratio ($SA/V$) . By calculating this change, you will gain a quantitative understanding of how the hyphal form gains an advantage in nutrient absorption and in its engagement with the host immune system.",
            "id": "4616027",
            "problem": "Candida albicans undergoes morphogenetic switching between a yeast form and a hyphal form. For a single yeast cell, approximate its geometry as a sphere of radius $r_{y} = 2.5\\,\\mu\\mathrm{m}$. For a single hyphal segment emerging from a mother cell, approximate its geometry as a right circular cylinder of radius $r_{h} = 1.0\\,\\mu\\mathrm{m}$ and length $L = 20\\,\\mu\\mathrm{m}$, capped distally by a hemisphere of the same radius. Assume the proximal base of the cylinder is attached to the mother cell and therefore does not contribute exposed end-cap surface area. Using standard geometric measures, determine the surface area-to-volume ratio $\\mathrm{SA}/V$ for each morphology and then compute the fold-change in $\\mathrm{SA}/V$ defined as\n$$F = \\frac{(\\mathrm{SA}/V)_{\\text{hypha}}}{(\\mathrm{SA}/V)_{\\text{yeast}}}.$$\nTreat the hyphal and yeast forms as having homogeneous cell wall transporter density per unit area and comparable metabolic demand per unit volume. Based on first principles, briefly justify how the calculated change in $\\mathrm{SA}/V$ would be expected to affect nutrient influx and host Pattern Recognition Receptor (PRR) engagement with exposed Pathogen-Associated Molecular Patterns (PAMPs). Use micrometers for all geometric quantities. Express the final numerical value of $F$ as a dimensionless decimal rounded to four significant figures.",
            "solution": "The problem is to determine the fold-change in the surface area-to-volume ratio ($\\mathrm{SA}/V$) when a *Candida albicans* cell switches from a yeast morphology to a hyphal morphology, based on simplified geometric models, and to provide a biophysical justification for the consequences of this change.\n\nFirst, we analyze the yeast form, approximated as a sphere of radius $r_{y}$.\nThe surface area of a sphere is given by the formula:\n$$ \\mathrm{SA}_{\\text{yeast}} = 4\\pi r_{y}^{2} $$\nThe volume of a sphere is given by:\n$$ V_{\\text{yeast}} = \\frac{4}{3}\\pi r_{y}^{3} $$\nThe surface area-to-volume ratio for the yeast form is therefore:\n$$ (\\mathrm{SA}/V)_{\\text{yeast}} = \\frac{4\\pi r_{y}^{2}}{\\frac{4}{3}\\pi r_{y}^{3}} = \\frac{3}{r_{y}} $$\nGiven the yeast radius $r_{y} = 2.5\\,\\mu\\mathrm{m}$, the numerical value of this ratio is:\n$$ (\\mathrm{SA}/V)_{\\text{yeast}} = \\frac{3}{2.5\\,\\mu\\mathrm{m}} = 1.2\\,(\\mu\\mathrm{m})^{-1} $$\n\nNext, we analyze the hyphal form. It is approximated as a composite structure consisting of a right circular cylinder of radius $r_{h}$ and length $L$, attached proximally to the mother cell, and capped distally by a hemisphere of the same radius $r_{h}$.\nThe total exposed surface area of the hypha, $\\mathrm{SA}_{\\text{hypha}}$, is the sum of the lateral surface area of the cylinder and the surface area of the distal hemispherical cap. The proximal circular base is stated to be unexposed and does not contribute.\nThe lateral surface area of the cylinder is $2\\pi r_{h} L$.\nThe surface area of the hemispherical cap is $\\frac{1}{2}(4\\pi r_{h}^{2}) = 2\\pi r_{h}^{2}$.\nThus, the total surface area of the hyphal form is:\n$$ \\mathrm{SA}_{\\text{hypha}} = 2\\pi r_{h} L + 2\\pi r_{h}^{2} = 2\\pi r_{h} (L + r_{h}) $$\nThe total volume of the hypha, $V_{\\text{hypha}}$, is the sum of the volume of the cylinder and the volume of the hemisphere.\nThe volume of the cylinder is $\\pi r_{h}^{2} L$.\nThe volume of the hemisphere is $\\frac{1}{2}(\\frac{4}{3}\\pi r_{h}^{3}) = \\frac{2}{3}\\pi r_{h}^{3}$.\nThus, the total volume of the hyphal form is:\n$$ V_{\\text{hypha}} = \\pi r_{h}^{2} L + \\frac{2}{3}\\pi r_{h}^{3} = \\pi r_{h}^{2} (L + \\frac{2}{3}r_{h}) $$\nThe surface area-to-volume ratio for the hyphal form is:\n$$ (\\mathrm{SA}/V)_{\\text{hypha}} = \\frac{2\\pi r_{h} (L + r_{h})}{\\pi r_{h}^{2} (L + \\frac{2}{3}r_{h})} = \\frac{2(L + r_{h})}{r_{h}(L + \\frac{2}{3}r_{h})} $$\nGiven the hyphal radius $r_{h} = 1.0\\,\\mu\\mathrm{m}$ and length $L = 20\\,\\mu\\mathrm{m}$, the numerical value of this ratio is:\n$$ (\\mathrm{SA}/V)_{\\text{hypha}} = \\frac{2(20\\,\\mu\\mathrm{m} + 1.0\\,\\mu\\mathrm{m})}{(1.0\\,\\mu\\mathrm{m})(20\\,\\mu\\mathrm{m} + \\frac{2}{3}(1.0\\,\\mu\\mathrm{m}))} = \\frac{2(21)}{20 + \\frac{2}{3}}\\,(\\mu\\mathrm{m})^{-1} = \\frac{42}{\\frac{62}{3}}\\,(\\mu\\mathrm{m})^{-1} = \\frac{126}{62}\\,(\\mu\\mathrm{m})^{-1} = \\frac{63}{31}\\,(\\mu\\mathrm{m})^{-1} \\approx 2.0323\\,(\\mu\\mathrm{m})^{-1} $$\n\nThe fold-change, $F$, is the ratio of the hyphal $\\mathrm{SA}/V$ to the yeast $\\mathrm{SA}/V$.\n$$ F = \\frac{(\\mathrm{SA}/V)_{\\text{hypha}}}{(\\mathrm{SA}/V)_{\\text{yeast}}} = \\frac{\\frac{2(L + r_{h})}{r_{h}(L + \\frac{2}{3}r_{h})}}{\\frac{3}{r_y}} = \\frac{2 r_{y} (L + r_{h})}{3 r_{h} (L + \\frac{2}{3}r_{h})} $$\nSubstituting the given numerical values:\n$$ F = \\frac{2 (2.5) (20 + 1.0)}{3 (1.0) (20 + \\frac{2}{3}(1.0))} = \\frac{5 \\times 21}{3 \\times (20 + \\frac{2}{3})} = \\frac{105}{3 \\times \\frac{62}{3}} = \\frac{105}{62} $$\nThe numerical value is $F \\approx 1.693548...$. Rounding to four significant figures, we get $F = 1.694$.\n\nThe result $F > 1$ indicates that the hyphal morphology has a significantly higher surface area-to-volume ratio than the yeast morphology. This has two primary biophysical consequences as requested:\n\n1.  **Nutrient Influx:** Assuming metabolic demand scales with cell volume and nutrient uptake scales with surface area (due to a homogeneous density of transporters), the $\\mathrm{SA}/V$ ratio is a direct measure of the cell's capacity for nutrient acquisition relative to its metabolic needs. A higher $\\mathrm{SA}/V$ ratio, as seen in the hyphal form, facilitates more efficient absorption of nutrients from the environment per unit of cellular machinery. This is a critical advantage for invasive growth, enabling the fungus to penetrate and colonize tissues where nutrients may be limited.\n\n2.  **Host PRR Engagement:** The surface of the pathogen is decorated with Pathogen-Associated Molecular Patterns (PAMPs), such as $\\beta$-glucans and mannans in the case of *C. albicans*. These PAMPs are recognized by Pattern Recognition Receptors (PRRs) on host immune cells. The total extent of interaction is proportional to the exposed surface area. The higher $\\mathrm{SA}/V$ ratio of the hyphal form means that, for a given cellular volume, a greater proportion of the organism's substance is presented at the host-pathogen interface. This leads to an amplified engagement with host PRRs, which can trigger a more potent or qualitatively different immune response compared to the more compact yeast form. The elongated shape of hyphae also fundamentally alters the nature of the physical interaction with immune cells, notably by frustrating phagocytosis.",
            "answer": "$$\\boxed{1.694}$$"
        },
        {
            "introduction": "Beyond physical invasion, *Candida albicans* deploys a molecular arsenal to overcome host defenses, with secreted aspartyl proteinases (Saps) being key virulence factors that degrade host tissues. To appreciate the destructive potential of these enzymes, it is essential to understand their efficiency, a property that can be described by the principles of enzyme kinetics. This exercise  allows you to apply the classic Michaelis-Menten model to calculate the rate of E-cadherin cleavage by a Sap protease, bridging the gap between theoretical biochemistry and the practical realities of microbial pathogenesis.",
            "id": "4615964",
            "problem": "Candida albicans secretes secreted aspartyl proteinases (Sap proteases) that cleave host adhesion proteins such as E-cadherin at mucosal surfaces, weakening barrier integrity during candidiasis. Consider a Sap protease characterized in vitro on an E-cadherin–derived peptide substrate under conditions where the enzyme exhibits simple single-substrate kinetics and rapidly reaches the steady state. Assume initial-rate conditions with negligible product accumulation and that the enzyme–substrate system follows a single-substrate mechanism with formation of an enzyme–substrate complex prior to catalysis.\n\nYou are given the following experimentally determined kinetic parameters for the Sap protease acting on the E-cadherin peptide:\n- Turnover number: $k_{\\mathrm{cat}} = 3.2\\,\\mathrm{s}^{-1}$.\n- Michaelis constant: $K_{M} = 15\\,\\mu\\mathrm{M}$.\n\nIn an infection microenvironment, the effective local concentration of accessible substrate sites is estimated to be $[S] = 2.5\\,\\mu\\mathrm{M}$, and the total concentration of catalytically competent enzyme active sites is $[E]_{T} = 25\\,\\mathrm{nM}$.\n\nStarting from the elementary enzyme–substrate binding and catalysis scheme and the steady-state approximation for the enzyme–substrate complex, derive the initial reaction velocity and then compute its numerical value for the conditions above. Express your final velocity in $\\mathrm{nM}\\,\\mathrm{s}^{-1}$ and round your answer to three significant figures.",
            "solution": "### Derivation of the Initial Velocity Equation\n\nThe problem describes a single-substrate enzyme reaction that can be represented by the following scheme, where $E$ is the enzyme, $S$ is the substrate, $ES$ is the enzyme-substrate complex, and $P$ is the product:\n$$\nE + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_{\\mathrm{cat}}}{\\longrightarrow} E + P\n$$\nHere, $k_1$ is the rate constant for the formation of the $ES$ complex, $k_{-1}$ is the rate constant for its dissociation back to $E$ and $S$, and $k_{\\mathrm{cat}}$ (also denoted $k_2$) is the catalytic rate constant for the formation of product $P$ from the $ES$ complex.\n\nThe rate of change of the concentration of the enzyme-substrate complex, $[ES]$, is given by:\n$$\n\\frac{d[ES]}{dt} = k_1 [E][S] - k_{-1}[ES] - k_{\\mathrm{cat}}[ES]\n$$\nThe problem states that the system rapidly reaches a steady state. The steady-state approximation assumes that the concentration of the intermediate $ES$ complex remains constant over time, i.e., $\\frac{d[ES]}{dt} = 0$. Applying this approximation gives:\n$$\n0 = k_1 [E][S] - (k_{-1} + k_{\\mathrm{cat}})[ES]\n$$\n$$\nk_1 [E][S] = (k_{-1} + k_{\\mathrm{cat}})[ES]\n$$\nThe total enzyme concentration, $[E]_T$, is the sum of the free enzyme concentration, $[E]$, and the enzyme bound in the complex, $[ES]$:\n$$\n[E]_T = [E] + [ES]\n$$\nSolving for $[E]$ gives $[E] = [E]_T - [ES]$. Substituting this into the steady-state equation:\n$$\nk_1 ([E]_T - [ES])[S] = (k_{-1} + k_{\\mathrm{cat}})[ES]\n$$\nExpanding the left side:\n$$\nk_1 [E]_T [S] - k_1 [ES][S] = (k_{-1} + k_{\\mathrm{cat}})[ES]\n$$\nRearranging to solve for $[ES]$:\n$$\nk_1 [E]_T [S] = (k_1 [S] + k_{-1} + k_{\\mathrm{cat}})[ES]\n$$\n$$\n[ES] = \\frac{k_1 [E]_T [S]}{k_1 [S] + k_{-1} + k_{\\mathrm{cat}}}\n$$\nTo simplify this expression, we divide the numerator and the denominator by $k_1$:\n$$\n[ES] = \\frac{[E]_T [S]}{[S] + \\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1}}\n$$\nThe Michaelis constant, $K_M$, is defined as $K_M = \\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1}$. Substituting $K_M$ into the expression for $[ES]$:\n$$\n[ES] = \\frac{[E]_T [S]}{K_M + [S]}\n$$\nThe initial reaction velocity, $v_0$, is the rate of formation of the product, which is proportional to the concentration of the $ES$ complex:\n$$\nv_0 = \\frac{d[P]}{dt} = k_{\\mathrm{cat}}[ES]\n$$\nSubstituting the derived expression for $[ES]$ into the velocity equation gives the final form of the Michaelis-Menten equation, as requested:\n$$\nv_0 = k_{\\mathrm{cat}} \\frac{[E]_T [S]}{K_M + [S]}\n$$\n\n### Calculation of the Initial Velocity\n\nThe problem requires computing the numerical value of $v_0$ using the given parameters and expressing the result in $\\mathrm{nM}\\,\\mathrm{s}^{-1}$.\n\nThe given parameters are:\n- $k_{\\mathrm{cat}} = 3.2\\,\\mathrm{s}^{-1}$\n- $K_M = 15\\,\\mu\\mathrm{M}$\n- $[S] = 2.5\\,\\mu\\mathrm{M}$\n- $[E]_T = 25\\,\\mathrm{nM}$\n\nTo ensure consistent units for the calculation, we can keep concentrations in $\\mu\\mathrm{M}$ for the fraction term, as the units will cancel. The enzyme concentration $[E]_T$ is given in $\\mathrm{nM}$, which matches the desired output unit for concentration.\n$$\nv_0 = (3.2\\,\\mathrm{s}^{-1}) \\times (25\\,\\mathrm{nM}) \\times \\frac{2.5\\,\\mu\\mathrm{M}}{15\\,\\mu\\mathrm{M} + 2.5\\,\\mu\\mathrm{M}}\n$$\nFirst, let's evaluate the dimensionless fraction:\n$$\n\\frac{[S]}{K_M + [S]} = \\frac{2.5}{15 + 2.5} = \\frac{2.5}{17.5}\n$$\nThis fraction can be simplified:\n$$\n\\frac{2.5}{17.5} = \\frac{25}{175} = \\frac{1 \\times 25}{7 \\times 25} = \\frac{1}{7}\n$$\nNow, substitute this back into the velocity equation:\n$$\nv_0 = (3.2\\,\\mathrm{s}^{-1}) \\times (25\\,\\mathrm{nM}) \\times \\frac{1}{7}\n$$\nCalculate the product of the numerical values:\n$$\nv_0 = \\frac{3.2 \\times 25}{7} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}\n$$\n$$\n3.2 \\times 25 = 80\n$$\n$$\nv_0 = \\frac{80}{7} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}\n$$\nNow, we compute the final numerical value:\n$$\nv_0 \\approx 11.42857... \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}\n$$\nThe problem asks to round the answer to three significant figures.\n$$\nv_0 \\approx 11.4 \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}\n$$\nThe calculated initial reaction velocity under the specified conditions is $11.4\\,\\mathrm{nM}\\,\\mathrm{s}^{-1}$.",
            "answer": "$$\n\\boxed{11.4}\n$$"
        },
        {
            "introduction": "The emergence of antifungal resistance is a major clinical concern that complicates the management of invasive candidiasis. *Candida albicans* can become resistant to common antifungals like fluconazole through multiple independent mechanisms, such as modifying the drug's target enzyme or actively pumping the drug out of the cell. This advanced problem  challenges you to think like a pharmacologist, first by reasoning whether the combined effect of these mechanisms is additive or multiplicative, and then by calculating the total impact on drug resistance. Mastering this concept is crucial for understanding how high-level resistance evolves and for predicting the efficacy of antifungal therapy.",
            "id": "4616017",
            "problem": "A clinical isolate of Candida albicans exhibits both a point mutation in the lanosterol 14-alpha-demethylase gene (ERG11), specifically a tyrosine-to-phenylalanine substitution at position $132$ (Y132F), and overexpression of the Adenosine Triphosphate (ATP)-Binding Cassette (ABC) efflux transporters Candida Drug Resistance $1$ and $2$ (CDR1 and CDR2). The minimum inhibitory concentration (MIC) is the minimal extracellular drug concentration that reduces the net growth rate to non-positive values, which can be interpreted as the concentration required to achieve a sufficiently low intracellular fungal ergosterol synthesis so that population growth is halted. The antifungal fluconazole inhibits ERG11; mutations in ERG11 can reduce binding affinity, while efflux pump overexpression reduces intracellular drug concentration. Both mechanisms are well-established in medical microbiology as contributors to increased fluconazole MIC.\n\nYou are provided literature-calibrated fold changes in fluconazole MIC for each mechanism, reported across independent studies with sample sizes reflecting the number of isolates tested:\n\n- ERG11 Y132F studies: fold increases $f_{T,1} = 8.0$ with $n_{T,1} = 30$, $f_{T,2} = 6.5$ with $n_{T,2} = 20$, and $f_{T,3} = 9.5$ with $n_{T,3} = 25$.\n- CDR1/2 overexpression studies: fold increases $f_{E,1} = 3.0$ with $n_{E,1} = 40$, $f_{E,2} = 4.0$ with $n_{E,2} = 35$, and $f_{E,3} = 2.5$ with $n_{E,3} = 25$.\n\nStarting from core pharmacological definitions and mechanisms of action, determine whether the combined impact on fluconazole MIC should be modeled additively or multiplicatively, and then calibrate each mechanism’s effect size using the sample-size-weighted geometric mean of the reported fold increases. Under the justified model, compute the predicted overall fold increase in fluconazole MIC for the isolate harboring both ERG11 Y132F and CDR1/2 overexpression. Round your final answer to three significant figures. Express the final result as a dimensionless fold-change (no units).",
            "solution": "The problem will be solved in three stages: first, justifying the interaction model for the combined resistance mechanisms; second, calibrating the effect size of each mechanism from the provided data; and third, computing the overall predicted effect.\n\n**1. Justification of the Interaction Model (Multiplicative vs. Additive)**\n\nThe two resistance mechanisms act at different points in the drug's mechanism of action. Let $C_{out}$ be the external drug concentration, and $C_{in}$ be the intracellular drug concentration. The Minimum Inhibitory Concentration (MIC) is the specific external concentration, $C_{out} = \\text{MIC}$, that results in a sufficient level of target inhibition to halt net population growth.\n\nFor a wild-type (susceptible) strain, let the MIC be $\\text{MIC}_{WT}$. This external concentration achieves a critical intracellular concentration, $C_{in,crit}$, which is just sufficient to inhibit the wild-type enzyme (ERG11) and stop growth.\n\nThe first mechanism is the overexpression of CDR1 and CDR2 efflux pumps. These pumps reduce drug accumulation by actively transporting fluconazole out of the cell. The effect of this mechanism is quantified by a fold-increase factor, $F_E$. This means that to achieve any given intracellular concentration $C_{in}$, a cell with overexpressed pumps requires an external concentration $F_E$ times greater than that required by a wild-type cell. For a cell with only this mechanism, the MIC, denoted $\\text{MIC}_E$, is the external concentration needed to reach the same critical intracellular concentration $C_{in,crit}$ at the still-wild-type target. Therefore, the relationship is:\n$$ \\text{MIC}_E = F_E \\times \\text{MIC}_{WT} $$\n\nThe second mechanism is a Y132F point mutation in the target enzyme, ERG11. This mutation reduces the binding affinity of fluconazole to the enzyme. Consequently, a higher intracellular drug concentration is needed to achieve the same degree of inhibition. This effect is quantified by a fold-increase factor, $F_T$. The new required critical intracellular concentration, $C_{in,crit,mut}$, is $F_T$ times higher than for the wild-type enzyme:\n$$ C_{in,crit,mut} = F_T \\times C_{in,crit} $$\nFor a cell with only this mutation (and wild-type efflux), the MIC, denoted $\\text{MIC}_T$, would be the external concentration needed to achieve this new, higher intracellular concentration. Thus:\n$$ \\text{MIC}_T = F_T \\times \\text{MIC}_{WT} $$\n\nNow, consider the clinical isolate possessing **both** mechanisms.\n- Due to the ERG11 mutation, the required intracellular concentration for growth inhibition is elevated to $C_{in,crit,mut} = F_T \\times C_{in,crit}$.\n- Due to the overexpressed efflux pumps, achieving any target intracellular concentration requires an external concentration that is scaled up by the factor $F_E$.\n\nTo inhibit the growth of this dual-resistance isolate, the external drug concentration must be high enough to achieve the intracellular concentration $C_{in,crit,mut}$. The efflux pumps impose their multiplicative \"cost\" on achieving this concentration. The required external concentration, $\\text{MIC}_{combined}$, is therefore $F_E$ times the external concentration that would be needed if only the target mutation were present ($\\text{MIC}_T$).\n$$ \\text{MIC}_{combined} = F_E \\times \\text{MIC}_{T} $$\nSubstituting the expression for $\\text{MIC}_T$ from above:\n$$ \\text{MIC}_{combined} = F_E \\times (F_T \\times \\text{MIC}_{WT}) = (F_T \\times F_E) \\times \\text{MIC}_{WT} $$\nThe overall fold increase in MIC is the ratio $\\frac{\\text{MIC}_{combined}}{\\text{MIC}_{WT}}$, which is equal to the product of the individual fold increases, $F_T \\times F_E$. Because the mechanisms act on sequential and independent steps (drug entry/accumulation and target binding), their effects are **multiplicative**.\n\n**2. Calibration of Individual Effect Sizes**\n\nThe problem specifies using the sample-size-weighted geometric mean to calibrate the effect size for each mechanism. For a set of values $\\{x_1, x_2, \\dots, x_k\\}$ with corresponding weights (sample sizes) $\\{w_1, w_2, \\dots, w_k\\}$, the weighted geometric mean is calculated as:\n$$ \\text{GM}_{\\text{weighted}} = \\left( \\prod_{i=1}^{k} x_i^{w_i} \\right)^{1 / \\sum_{i=1}^{k} w_i} = \\exp\\left( \\frac{\\sum_{i=1}^{k} w_i \\ln(x_i)}{\\sum_{i=1}^{k} w_i} \\right) $$\n\n**For the ERG11 Y132F mutation (Mechanism T):**\nData: $f_{T,1} = 8.0$ ($n_{T,1} = 30$), $f_{T,2} = 6.5$ ($n_{T,2} = 20$), and $f_{T,3} = 9.5$ ($n_{T,3} = 25$).\nTotal weight: $N_T = 30 + 20 + 25 = 75$.\nThe calibrated effect size, $F_T$, is:\n$$ F_T = \\exp\\left( \\frac{30 \\ln(8.0) + 20 \\ln(6.5) + 25 \\ln(9.5)}{75} \\right) $$\n$$ F_T \\approx \\exp\\left( \\frac{30(2.07944) + 20(1.87180) + 25(2.25129)}{75} \\right) $$\n$$ F_T \\approx \\exp\\left( \\frac{62.3832 + 37.4360 + 56.2823}{75} \\right) = \\exp\\left( \\frac{156.1015}{75} \\right) \\approx \\exp(2.081353) \\approx 8.01512 $$\n\n**For the CDR1/2 overexpression (Mechanism E):**\nData: $f_{E,1} = 3.0$ ($n_{E,1} = 40$), $f_{E,2} = 4.0$ ($n_{E,2} = 35$), and $f_{E,3} = 2.5$ ($n_{E,3} = 25$).\nTotal weight: $N_E = 40 + 35 + 25 = 100$.\nThe calibrated effect size, $F_E$, is:\n$$ F_E = \\exp\\left( \\frac{40 \\ln(3.0) + 35 \\ln(4.0) + 25 \\ln(2.5)}{100} \\right) $$\n$$ F_E \\approx \\exp\\left( \\frac{40(1.09861) + 35(1.38629) + 25(0.91629)}{100} \\right) $$\n$$ F_E \\approx \\exp\\left( \\frac{43.9444 + 48.5202 + 22.9073}{100} \\right) = \\exp\\left( \\frac{115.3719}{100} \\right) \\approx \\exp(1.153719) \\approx 3.17007 $$\n\n**3. Computation of the Overall Fold Increase**\n\nUsing the multiplicative model, the total predicted fold increase, $F_{total}$, is the product of the individual calibrated effects:\n$$ F_{total} = F_T \\times F_E $$\n$$ F_{total} \\approx 8.01512 \\times 3.17007 \\approx 25.4083 $$\nThe problem requires the final answer to be rounded to three significant figures.\n$$ F_{total} \\approx 25.4 $$",
            "answer": "$$\\boxed{25.4}$$"
        }
    ]
}